The FDA approved imlunestrant plus abemaciclib in breast cancer and photodynamic therapy in skin cancer, and more.
Quiz|Articles|August 1, 2026
OncLive Weekly News Quiz (7/31/2026): Did You Catch This Week's Melanoma, Head and Neck, and Gastric Cancer Updates?
Author(s)OncLive Staff
Fact checked by: Chris Ryan
Key Takeaways
- ”, varied openers, complete sentences, ending with periods).
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Advertisement
The FDA's Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC) reviewed data from the phase 1/2 IGNYTE trial (NCT03767348) evaluating vusolimogene oderparepvec (RP1) plus nivolumab (Opdivo) in advanced cutaneous melanoma that progressed on an anti–PD-1–based regimen. What was the outcome of the committee's vote?
Advertisement
Related to this article
The FDA has approved lirafugratinib (Lyrfigtu) for the treatment of adult patients with previously treated unresectable, locally advanced or metastatic cholangiocarcinoma harboring an FGFR2 gene fusion or other rearrangement.
Shailender Bhatia, MD, discusses next steps for adjuvant therapy research in light of the phase 3 ADAM trial data and broader implications for Merkel cell carcinoma.
Shailender Bhatia, MD, discusses ADAM trial design, key efficacy and safety findings, and treatment implications in Merkel cell carcinoma.
Lanreotide injection, a generic formulation referencing lanreotide, was approved by the FDA for GEP-NETs management.
The FDA granted final approval to aLutetium Lu 177 dotatate biosimilar for patients with SSTR-positive GEP-NETs.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Udai S. Kammula, MD, FACS, discusses TIL therapy outcomes, the UMIS biomarker, and treatment implications in metastatic uveal melanoma.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Lirafugratinib for Pretreated, Locally Advanced or Metastatic Cholangiocarcinoma
2
Dr Mayer on the FDA Approval of Camizestrant for ESR1-Mutated Breast Cancer
3
INCB161734 Holds Potential Significance for KRAS G12D–Mutated mPDAC Management
4
Dr Barot on CNS Outcomes With Palbociclib in HER2+ Breast Cancer
5